CLAIMS

1. Use of a compound for the manufacture of a medicament for treatment of a disease or a condition susceptible to amelioration by AMP-activated protein kinase (AMPK) activators, characterized in that the compound is adenine and/or a pharmaceutically acceptable salt thereof, and the compound serves as a sole active ingredient for the treatment,

wherein the disease or the condition is selected from the group consisting of an inflammatory condition or disease, pre-diabetes, type 2 diabetes, metabolic syndrome, obesity, Alzheimer's disease, a neurodegenerative disease, scar formation during wound healing, wound, a disease or condition associated with excessive ROS, breast cancer, and a combination thereof, and

wherein the inflammatory condition or disease is selected from the group consisting of ankylosing spondylitis, arthritis, asthma, atherosclerosis, inflammatory bowel disease, colitis, dermatitis, diverticulitis, fibromyalgia, hepatitis, irritable bowel syndrome, systemic lupus erythematous, nephritis, and a combination thereof,

provided that if the disease or the condition is scar formation during wound healing, the medicament is to be used to prevent scar formation during wound healing,

provided that if the disease or the condition is wound, the medicament is to be used to enhance wound healing, and

provided that if the disease or the condition is the disease or condition associated with excessive ROS, the medicament is to be used to protect and treat cells from ROS injury in a mammal, and the disease or condition associated with excessive ROS is selected from the group consisting of NARP (neurogenic muscle weakness, ataxia and retinitis pigmentosa), MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes), MERRF (myoclonic epilepsy and ragged-red fibers), LHON (Leber hereditary optic neuropathy), KSS (Kearns-Sayre syndrome), Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Friedreich's ataxia, and a combination thereof.

2. The use of claim 1, wherein the disease or the condition is the inflammatory condition or disease selected from the group consisting of ankylosing spondylitis, arthritis, asthma, atherosclerosis, inflammatory bowel disease, colitis, dermatitis, diverticulitis, fibromyalgia, hepatitis, irritable bowel syndrome, systemic lupus erythematous, nephritis, and a combination thereof.

3. The use of claim 1, wherein the disease or the condition is pre-diabetes, type 2 diabetes, metabolic syndrome, or a combination thereof.

4. The use of claim 1, wherein the disease or the condition is obesity.

5. The use of claim 1, wherein the disease or the condition is Alzheimer's disease.

6. The use of claim 1, wherein the disease or the condition is the neurodegenerative disease.

7. The use of claim 1, wherein the medicament is to be used to prevent scar formation during wound healing.

8. The use of claim 1, wherein the medicament is to be used to enhance wound healing.

9. The use of claim 1, wherein the disease or condition is the disease or condition associated with excessive ROS, wherein the medicament is to be used to protect and treat cells from ROS injury in a mammal, and the disease or condition associated with excessive ROS is selected from the group consisting of NARP (neurogenic muscle weakness, ataxia and retinitis pigmentosa), MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes), MERRF (myoclonic epilepsy and ragged-red fibers), LHON (Leber hereditary optic neuropathy), KSS (Kearns-Sayre syndrome), Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Friedreich's ataxia, and a combination thereof.

10. The use of claim 1, wherein the disease or the condition is breast cancer.